TSE:FRX Stock Earnings Estimates Increased by HC Wainwright

Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Stock analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a note issued to investors on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of $0.49 per share for the year, up from their prior forecast of $0.29. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2026 earnings at $0.21 EPS, Q1 2027 earnings at $0.24 EPS, Q2 2027 earnings at $0.33 EPS and FY2027 earnings at $1.43 EPS.

Fennec Pharmaceuticals Stock Performance

Shares of FRX stock opened at C$19.29 on Friday. The stock has a market cap of C$681.03 million, a price-to-earnings ratio of 643.00 and a beta of 3.90. The stock has a 50-day moving average of C$15.15 and a 200-day moving average of C$13.24. Fennec Pharmaceuticals has a 1-year low of C$7.59 and a 1-year high of C$19.84.

Insider Buying and Selling

In other Fennec Pharmaceuticals news, insider Robert Christopher Andrade sold 106,844 shares of the company’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of C$16.63, for a total transaction of C$1,776,815.72. Following the sale, the insider owned 217,675 shares of the company’s stock, valued at approximately C$3,619,935.25. This represents a 32.92% decrease in their ownership of the stock. Also, insider Pierre Sayad sold 12,000 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of C$17.18, for a total value of C$206,160.00. Following the transaction, the insider owned 9,519 shares in the company, valued at C$163,536.42. The trade was a 55.76% decrease in their ownership of the stock. 16.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Fennec Pharmaceuticals

An institutional investor recently bought a new stake in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. purchased a new stake in Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned about 0.30% of Fennec Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 16.86% of the company’s stock.

About Fennec Pharmaceuticals

(Get Free Report)

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.

Read More

Earnings History and Estimates for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.